<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Intractable Rare Dis Res</journal-id>
<journal-id journal-id-type="iso-abbrev">Intractable Rare Dis Res</journal-id>
<journal-id journal-id-type="publisher-id">irdr</journal-id>
<journal-id journal-id-type="hwp">irdr</journal-id>
<journal-title-group>
<journal-title>Intractable &amp; Rare Diseases Research</journal-title>
</journal-title-group>
<issn pub-type="ppub">2186-3644</issn>
<issn pub-type="epub">2186-361X</issn>
<publisher>
<publisher-name>International Research and Cooperation Association for Bio &amp; Socio-Sciences Advancement</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27672538</article-id>
<article-id pub-id-type="pmc">4995416</article-id>
<article-id pub-id-type="doi">10.5582/irdr.2016.01045</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Review of targeted treatments in fragile X syndrome</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Ligsay</surname>
<given-names>Andrew</given-names>
</name>
<xref ref-type="aff" rid="a1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="a2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hagerman</surname>
<given-names>Randi J</given-names>
</name>
<xref ref-type="aff" rid="a1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="a3">
<sup>3</sup>
</xref>
<xref ref-type="corresp" rid="c1">*</xref>
</contrib>
<aff id="a1"><label>1</label> Medical Investigation of Neurodevelopmental Disorders (MIND) Institute, University of California, Davis Medical Center, Sacramento, CA, USA</aff>
<aff id="a2"><label>2</label> University of California, Davis School of Medicine, Sacramento, CA, USA</aff>
<aff id="a3"><label>3</label> Department of Pediatrics, University of California, Davis Medical Center, Sacramento, CA, USA</aff>
</contrib-group>
<author-notes>
<corresp id="c1"><label>*</label><italic>Address correspondence to:</italic> Dr. Randi J Hagerman, Medical Investigation of Neurodevelopmental Disorders (MIND) Institute, University of California, Davis Medical Center, 2825 50th Street, Sacramento, CA 95817, USA. E-mail: <email>rjhagerman@ucdavis.edu</email></corresp>
</author-notes>
<pub-date pub-type="ppub">
<month>8</month>
<year>2016</year>
</pub-date>
<volume>5</volume>
<issue>3</issue>
<fpage>158</fpage>
<lpage>167</lpage>
<history>
<date date-type="received">
<day>10</day>
<month>6</month>
<year>2016</year>
</date>
<date date-type="rev-recd">
<day>28</day>
<month>7</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>30</day>
<month>7</month>
<year>2016</year>
</date>
</history>
<permissions>
<copyright-statement>2016, International Research and Cooperation Association for Bio &amp; Socio-Sciences Advancement</copyright-statement>
<copyright-year>2016</copyright-year>
</permissions>
<abstract>
<title>Summary</title>
<p>Fragile X syndrome (FXS) is the most common inherited form of intellectual disability, and is the leading single-gene cause of autism spectrum disorders. It is due to a loss of the fragile X mental retardation protein, which leads to molecular, behavioral, and cognitive deficits in these patients. Improvements in our understanding of its pathophysiology have led to the development of numerous targeted treatments in FXS as highlighted by metabotropic glutamate receptor antagonists and gamma-Aminobutyric acid receptor modulators. This review will summarize relevant pre-clinical data and results from clinical trials in human subjects with FXS. It will also highlight upcoming studies and future directions for clinical trials as well.</p>
</abstract>
<kwd-group kwd-group-type="author">
<kwd>Fragile X syndrome</kwd>
<kwd>targeted treatments</kwd>
<kwd>clinical trials</kwd>
</kwd-group>
<counts>
<fig-count count="0"></fig-count>
<table-count count="1"></table-count>
<ref-count count="84"></ref-count>
<page-count count="10"></page-count>
</counts>
</article-meta>
</front>
</article>
</pmc-articleset>